Maitreya Medicare Limited is a rapidly scaling multi-super-specialty healthcare provider established in **2019**. Headquartered in Surat, the company has evolved from a single-facility operation into a regional healthcare network serving **South Gujarat and Maharashtra**. The company specializes in high-acuity tertiary care, with a strategic focus on **Cardiology, Neurology, and Critical Care**, which collectively contribute **60-70%** of total revenue. --- ### **Strategic Asset Portfolio and Capacity Expansion** Maitreya has executed an aggressive growth trajectory, expanding from **125 beds in 2023** to an aggregate capacity of **555 beds** across seven units as of late **2025**. The company utilizes a hybrid model of owned facilities and asset-light **Operations & Management (O&M)** agreements. | Hospital / Unit | Location | Capacity | Model / Status | | :--- | :--- | :--- | :--- | | **Maitreya Medicare (Flagship)** | Surat, GJ | **125 Beds** | Owned; NABH Accredited | | **Maitreya Hospital (Subsidiary)** | Valsad, GJ | **125 Beds** | Wholly Owned; Opened **March 2026** | | **Prannath Hospital** | Surat, GJ | **100 Beds** | O&M / Clinical Partner | | **Vinish Healthcare (Smit Hospital)** | Nandurbar, MH | **85 Beds** | Clinical Services Agreement | | **KLS Memorial Hospital** | Mumbai, MH | **70 Beds** | O&M Agreement; Entry into Mumbai | | **Tulip Agility (Tulip Health)** | Surat, GJ | **50 Beds** | **52% Subsidiary**; Geriatric/Palliative | | **Varanasi Cluster (3 Units)** | Varanasi, UP | **-** | O&M Agreement (Multi-specialty/IVF) | --- ### **Clinical Specialization and Service Spectrum** The company operates an integrated healthcare model spanning primary, secondary, and tertiary care across more than **18 specialties**. * **High-Acuity Core:** Intervention Cardiology, Cardiothoracic Surgery, Neuro-intervention (endoscopic spine and micro-neurosurgery), and Neuro-intensive care. * **Critical Care Infrastructure:** Advanced capabilities including **ECMO (Extracorporeal Membrane Oxygenation)**, **CRRT (Continuous Renal Replacement Therapy)**, and a dedicated **20-bed ICU** setup. * **Surgical & Medical Excellence:** Oncosurgery, Gastroenterology, Nephrology, Urology, and High-Risk Obstetrics. * **Diagnostics & Ancillary:** High-end health screenings via **Tulip Health Check**, a **6-bed Dialysis unit**, IVF, Dexa Scan, Mammography, and comprehensive neuro-diagnostics (**EEG, EMG, NCS**). * **New Frontiers:** The company is currently introducing **Radiotherapy** and **Renal Transplant** services at the Prannath Hospital unit to complete its specialty spectrum. --- ### **Operational Performance and Efficiency Metrics** Maitreya focuses on optimizing yield through high-margin specialties and digital integration. * **ARPOB:** As of **March 2025**, the Average Revenue Per Occupied Bed stood at **₹28,041**. * **Utilization Targets:** Current bed occupancy is approximately **55%**, with a management target to reach **100% operational capacity** by the end of **2026**. * **Digital Leadership:** The flagship facility is the first in Surat to receive the **NABH Digital Health Accreditation (Silver Category)**, positioning the group as a first-mover in digital patient care standards. * **Public Health Integration:** The company is a registered provider under the **Ayushman Bharat (PM-JAY)** scheme, ensuring a steady volume of need-based healthcare cases. --- ### **Financial Profile and Capital Structure** Maitreya Medicare listed on the **NSE Emerge Platform** on **November 7, 2023**, raising capital through an IPO of **1,816,000 equity shares** priced at a premium of **₹68 - ₹72**. #### **Key Financial Indicators** | Metric (Consolidated) | FY 2022-23 | FY 2023-24 | Q4 FY24 (Quarterly) | | :--- | :--- | :--- | :--- | | **Total Revenue** | **₹39.04 Cr** | **₹46.75 Cr** | **₹12.54 Cr** | | **PAT** | **₹4.18 Cr** | **₹3.17 Cr** | **(₹1.07 Cr)** | | **PAT Margin** | **10.7%** | **6.8%** | **-9%** | *Note: Recent PAT pressure is attributed to a one-time **Bad Debts adjustment of ₹1.70 Cr** and aggressive pre-operative expenses for new facilities.* #### **Debt and Liquidity Management** The company maintains several secured loans for medical equipment and infrastructure, primarily with **HDFC Bank**, **IndusInd**, and **Kotak Mahindra**, with interest rates ranging from **8.80% to 12.05%**. These are secured by fixed deposits (**₹60 Lakhs**), current assets, and personal guarantees from directors. To prioritize growth, the board opted **not to recommend dividends** for FY24, reinvesting all cash flows into expansion. --- ### **Growth Strategy: The "Tier II/III" Roadmap** The company’s strategy is built on geographic clustering and service deepening: 1. **Geographic Expansion:** Moving beyond South Gujarat into the **Mumbai metro** and **Varanasi** markets via asset-light O&M models. 2. **Specialized Care Segments:** Scaling the **Tulip Agility** brand (52% subsidiary) to capture the rising demand for geriatric, rehabilitative, and palliative care. 3. **Technology Upgrades:** Recent installations of **Cathlabs** at KLS Memorial and Prannath Hospital to boost invasive cardiology revenue. 4. **Human Capital:** Implementation of the **ESOS 2026 (Employee Stock Option Scheme)**, authorizing up to **10,16,400 options** to retain top-tier medical talent. --- ### **Risk Management and Governance** Maitreya maintains a comprehensive Risk Register to monitor industry and regulatory shifts. * **Regulatory Risks:** Exposure to government-mandated **price caps** on implants and medicines, and margin pressures from state-sponsored insurance schemes. * **Legal & Compliance:** The company is a co-respondent in several **Consumer Court** cases (primarily insurance-related); management anticipates no material liability. * **Audit & Transparency:** Following the resignation of the internal auditor in **August 2025**, the company is strengthening its internal controls. It has also initiated interest provisions under the **MSMED Act, 2006** to ensure strict vendor compliance. * **Market Competition:** Intense competition for **highly skilled professionals** in the Tier I and Tier II markets remains a primary operational challenge.